Cancer Development In Organ Transplant Recipients

July 25, 2019 updated by: University of Zurich
The investigators will determine the cancer risk in organ transplant recipients compared to the general population with the help of statistical analysis. Secondly the investigators will try to characterize the different cancer types.

Study Overview

Status

Completed

Conditions

Detailed Description

This cohort analyses will focus on incident and recurrent cases of development of non-skin cancer over time. We will consider time to first formation of non-skin solid cancer after solid organ transplantation as well as the cumulative number of non-skin solid cancer formation over time. Both aspects are equally important and will be reflected in the analytic methods of this study. Theses analyses will be restricted to the most prevalent transplantation types of heart, kidney, liver, and lung.

Study Type

Observational

Enrollment (Actual)

1800

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Switzerland
      • Zurich, Switzerland, 8091
        • University Hospital Zurich, Division of Dermatology

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

All solid organ transplant recipients in Switzerland since 2008 who have given their consent to be included in the study.

Description

Inclusion Criteria:

We will select all patients within the STCS based on the date of the first solid organ transplantation. Patients with multiple organ transplantations will be included as well. Patients contribute to the study observation time until death or end of follow-up due to other reasons.

Exclusion Criteria:

We will exclude patients with non-solid organ transplantation (e.g. hematopoietic stem cell transplantation), because the detailing of information in the STCS is insufficient to allow for detailed analysis of cancer development and control of relevant confounders. We will exclude

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Cohort
  • Time Perspectives: Prospective

Cohorts and Interventions

Group / Cohort
Organ transplant recipients
Follow-ups in regular intervals following the organ transplant date.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Number of solid cancers
Time Frame: Ten Year followup
Number of solid cancers
Ten Year followup

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University of Zurich

Collaborators

University Hospital, Geneva
University Hospital Inselspital, Berne
University Hospital, Basel, Switzerland
University of Lausanne Hospitals
Cantonal Hospital of St. Gallen

Investigators

  • Principal Investigator: Gunther FL Hofbauer, MD, University Hospital, Zürich

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 1, 2008

Primary Completion (Actual)

May 1, 2018

Study Completion (Actual)

July 1, 2019

Study Registration Dates

First Submitted

December 18, 2014

First Submitted That Met QC Criteria

January 5, 2015

First Posted (Estimate)

January 7, 2015

Study Record Updates

Last Update Posted (Actual)

July 29, 2019

Last Update Submitted That Met QC Criteria

July 25, 2019

Last Verified

July 1, 2019

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • FUP062
  • snctp000000587 (Other Identifier: Swiss National Clinical Trials Portal)

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Kidney Cancer

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Oman

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe